RxDoctor Payments Data

Anu Batra, MD

Hematology & Oncology · Mesa, AZNPI 1720386857

Payments from drug & device makers

$30,242in general payments, 2019–2025

Across 857 payments — averaging $35.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$10K
  • AstraZeneca$5K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Pfizer$958
  • Merck$894
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$13,87546%
  • Food & beverage$15,67552%
  • Education$6922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.41$9,870
AstraZeneca(2 entities)56$4,771
Johnson & Johnson(2 entities)61$2,197
Novartis62$1,179
Pfizer51$958
Merck49$894
Bristol Myers Squibb62$881
Genentech USA, Inc.30$537
AbbVie30$527
Amgen31$505
E.r. Squibb & Sons, L.L.C.42$501
Eisai Inc.23$486
Sanofi22$477
Seagen Inc.20$471
Gilead(2 entities)17$378
Astellas Pharma US Inc14$371
GSK16$330
Takeda Pharmaceuticals U.S.A., Inc.14$276
Pharmacyclics LLC, An Abbvie Company14$258
Array Biopharma Inc14$254
Incyte Corporation13$231
Exelixis Inc.9$223
Bayer11$218
Blueprint Medicines Corporation9$200
Regeneron Healthcare Solutions, Inc.7$180
Ipsen Biopharmaceuticals, Inc9$177
Springworks Therapeutics, Inc.8$174
Puma Biotechnology, Inc.8$168
Beone Medicines USA, Inc.6$148
EMD Serono, Inc.7$137
Tempus AI, Inc2$133
AVEO Pharmaceuticals, Inc.6$132
Lilly USA, LLC6$132
Jazz Pharmaceuticals Inc.6$130
Rigel Pharmaceuticals, Inc.6$126
Beigene USA, Inc.5$122
Tersera Therapeutics LLC4$99
Taiho Oncology, Inc.4$96
Stemline Therapeutics Inc.4$96
Chiesi USA, Inc.4$78
Sobi, Inc4$77
ADC Therapeutics America, Inc.3$69
Karyopharm Therapeutics Inc.2$54
Global Blood Therapeutics, Inc.3$53
Myovant Sciences Inc.3$52
Sumitomo Pharma America, Inc.2$46
Boehringer Ingelheim2$45
CTI Biopharma Corp.2$42
Davol Inc.1$41
Adaptive Biotechnologies Corporation2$39
Mirati Therapeutics, Inc.2$38
Deciphera Pharmaceuticals Inc.2$37
Organon2$36
Geron Corporation1$34
Morphosys, US Inc.2$32
Epizyme, Inc.2$29
Tesaro, Inc.1$29
Coherus Oncology, Inc.1$27
Legend Biotech USA Inc.1$27
Kyowa Kirin, Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,242 in reported general payments places this provider in the 50th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,379,684
Medicare patients
361
Services billed
83,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide23$269,000
SprycelDasatinib11$211,667
CalquenceAcalabrutinib Maleate11$193,161
LumakrasSotorasib11$112,092
EliquisApixaban118$80,487
XareltoRivaroxaban62$55,704
Letrozole98$3,033
Tamoxifen Citrate39$1,112
Hydroxyurea30$1,016
Dexamethasone50$914
Anastrozole47$809
Acyclovir86$742
Prochlorperazine Maleate29$715
ValacyclovirValacyclovir Hcl14$668
Gabapentin56$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$501$211,66711 claims
AstraZenecaCalquence$4,771$193,16111 claims
AmgenLumakras$505$112,09211 claims
PfizerEliquis$958$80,487118 claims
Johnson & JohnsonXarelto$2,197$55,70462 claims
Lilly USA, LLCOlanzapine$132$11011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →